Stock-Based Compensation for Revolution Medicines (RVMD)
Stock-Based Compensation for Revolution Medicines (RVMD): headline value $93.31M · YoY +49.5%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingStock-Based CompensationSwitch metric
Latest period
$93.31M
YoY change
+49.5%
5Y CAGR
+67.8%
Peak year (2025)
$118.39M
Latest annual
$118.39M
Stock-Based Compensation history chart for Revolution Medicines (RVMD) from 2017 to 2025
Stock-Based Compensation history table for Revolution Medicines (RVMD) from 2017 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $118.39M | +49.5% | +$39.19M | ||
| 2024 | $79.20M | +28.2% | +$17.43M | ||
| 2023 | $61.77M | +98.0% | +$30.58M | ||
| 2022 | $31.20M | +50.5% | +$10.47M | ||
| 2021 | $20.72M | +133.2% | +$11.84M | ||
| 2020 | $8.89M | +181.1% | +$5.72M | ||
| 2019 | $3.16M | +269.7% | +$2.31M | ||
| 2018 | $855,000 | +506.4% | +$714,000 | ||
| 2017 | $141,000 | — | — |
Stock-Based Compensation values are taken from Revolution Medicines's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Revolution Medicines (RVMD) stock-based compensation totalled $118.39M – surged 49.5% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Revolution Medicines stock-based compensation compounded at +67.8% per year, with the latest reading among the more recent periods of the dataset.
The highest annual stock-based compensation of $118.39M was reported in 2025. The lowest in the available history was $141,000 in 2017.
Within Healthcare, Revolution Medicines (RVMD) ranks 5th among 8 peers we track. The peer median for stock-based compensation is $313.00M.
Revolution Medicines Stock-Based Compensation by Year
Revolution Medicines Stock-Based Compensation 2025: $118.39M
Revolution Medicines stock-based compensation in 2025 was $118.39M, surged 49.5% from 2024. This figure represents the highest annual value in the available history.
Revolution Medicines Stock-Based Compensation 2024: $79.20M
Revolution Medicines stock-based compensation in 2024 was $79.20M, grew 28.2% from 2023.
Revolution Medicines Stock-Based Compensation 2023: $61.77M
Revolution Medicines stock-based compensation in 2023 was $61.77M, surged 98.0% from 2022.
Revolution Medicines Stock-Based Compensation 2022: $31.20M
Revolution Medicines stock-based compensation in 2022 was $31.20M, surged 50.5% from 2021.
Revolution Medicines Stock-Based Compensation 2021: $20.72M
Revolution Medicines stock-based compensation in 2021 was $20.72M.
See more financial history for Revolution Medicines (RVMD).
Sector peers — Stock-Based Compensation
Companies in the same sector as Revolution Medicines, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group (UNH) | $971.00M | Healthcare |
| AbbVie (ABBV) | $955.00M | Healthcare |
| Eli Lilly (LLY) | $626.00M | Healthcare |
| AstraZeneca (AZN) | $0 | Healthcare |
| Merck & Co. (MRK) | $0 | Healthcare |
| Novo Nordisk (NVO) | $0 | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Frequently asked questions
What is Revolution Medicines's stock-based compensation?
Latest reported stock-based compensation for Revolution Medicines (RVMD) is $93.31M (period ending March 31, 2026).
How has Revolution Medicines stock-based compensation changed year-over-year?
Revolution Medicines (RVMD) stock-based compensation changed +49.5% year-over-year on the latest annual filing.
What is the long-term growth rate of Revolution Medicines stock-based compensation?
Revolution Medicines (RVMD) stock-based compensation compound annual growth rate is +67.8% over the most recent 5 years available.
When did Revolution Medicines stock-based compensation hit its highest annual value?
Revolution Medicines stock-based compensation reached its highest annual value of $118.39M in 2025.
What was Revolution Medicines stock-based compensation in 2024?
Revolution Medicines (RVMD) stock-based compensation in 2024 was $79.20M.
What was Revolution Medicines stock-based compensation in 2025?
Revolution Medicines (RVMD) stock-based compensation in 2025 was $118.39M.
RVMD Key Financials
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
RVMD Overview
Company profile, financial tools, and key metrics
RVMD What If Invested
What if you had invested $1,000? See historical returns from any date.
RVMD How It Makes Money
Discover visual breakdown — where revenue comes from and where it goes.
RVMD Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
RVMD Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
RVMD Daily Price Character
Explosive · 50.7% historical win rate (green days). Streaks & record days.
RVMD Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.